Sarepta Therapeutics (SRPT) Interest Expenses (2010 - 2022)

Sarepta Therapeutics' Interest Expenses history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Interest Expenses rose 4.56% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 4.56% YoY), while the FY2025 annual figure was $1.1 billion, up 160.43% from the prior year.
• Interest Expenses for Q1 2026 stood at $1.0 billion, up from $13.0 million in the prior quarter.
• The five-year high for Interest Expenses was $1.1 billion in Q2 2025, with the low at -$38.8 million in Q4 2023.
• The 5-year median for Interest Expenses is $13.0 million (2025), against an average of $304.1 million.
• The sharpest annual moves came in 2023 and 2025: Interest Expenses tumbled 1762.92% in 2023, then soared 23323.01% in 2025.
• Sarepta Therapeutics' Interest Expenses stood at -$2.1 million in 2022, then sank by 1762.92% to -$38.8 million in 2023, then climbed by 13.47% to -$33.6 million in 2024, then surged by 138.78% to $13.0 million in 2025, then surged by 7851.28% to $1.0 billion in 2026.
• Business Quant data shows SRPT's Interest Expenses at $1.0 billion in Q1 2026, $13.0 million in Q4 2025, and $1.1 billion in Q3 2025.